Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for SomniGroup International Inc. (SGI:NYSE), powered by AI.
SomniGroup International Inc. is currently trading at $74.97. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for SomniGroup International Inc. on Alpha Lenz.
SomniGroup International Inc.'s P/E ratio is 40.2.
“SomniGroup International Inc. trades at a P/E of 40.2 (premium valuation) with strong ROE of 20.9%. 3Y revenue CAGR of 15.0% highlights clear growth momentum.”
Ask for details →SomniGroup International Inc. is a key player in the global pharmaceutical and healthcare industry. Its primary function is to research, develop, and market innovative healthcare solutions aimed at improving health outcomes worldwide. SomniGroup is well-regarded for its development of life-saving medications and therapies focused on chronic and rare diseases, as well as its cutting-edge contributions to vaccine technology. The company has a diverse portfolio that includes over-the-counter pharmaceuticals, prescription drugs, and biotech products, serving a broad range of sectors from hospitals and clinics to retail pharmacies and healthcare providers. Headquartered strategically to leverage global supply chains, SomniGroup International Inc. plays a vital role in advancing medical science and enhancing public healthcare systems. By continually investing in R&D and forming strategic partnerships, the company remains at the forefront of delivering health innovations that meet both current and future needs of the medical industry.
“SomniGroup International Inc. trades at a P/E of 40.2 (premium valuation) with strong ROE of 20.9%. 3Y revenue CAGR of 15.0% highlights clear growth momentum.”
Ask for details →SomniGroup International Inc. (ticker: SGI) is a company listed on NYSE in the Consumer Cyclical sector (Furnishings, Fixtures & Appliances). It has approximately 12,000 employees. Market cap is $15.4B.
The current price is $74.97 with a P/E ratio of 40.21x and P/B of 4.97x.
ROE is 20.95% and operating margin is 10.02%. Annual revenue is $7.5B.